


AMENDMENT OF THE CLAIMS:

1. (Currently amended) A compound of formula (I):



wherein:

R¹ represents is substituted or unsubstituted heterocyclyl;

Y represents is -(CR_{na}R_{nb})_n-;

R_{na} and R_{nb} are each independently hydrogen or C₁₋₆alkyl;

n is an integer from 1 to 5;

R² represents is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R³ and R⁴ each independently represent are hydrogen or C₁₋₆alkyl;
and salts and solvates thereof;

with the proviso that the following compounds are excluded;

N-{{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-[2-(2-oxoimidazolidin-1-yl)ethyl]urea;



tert-butyl 4-({{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino}carbonyl]amino}methyl)piperidine-1-carboxylate;

N-{{[1-(cyclopropylcarbonyl)piperidin-4-yl]methyl}-N'-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}urea, and;

N-{{(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-N'-{{[1-(methylsulfonyl)piperidin-4-yl]methyl}urea.

2. (Original) A compound of formula (I) according to claim 1 wherein R¹ is unsubstituted or substituted piperidinyl.

3. (Currently amended) A compound of formula (I) according to claim 1 or ~~claim 2~~ wherein R¹ is selected from 1-(methylaminocarbonyl)piperidin-4-yl, 1-(diethylaminocarbonyl)piperidin-4-yl, 1-(methoxycarbonyl)piperidin-4-yl, 1-(cyclopropylaminocarbonyl)piperidin-4-yl, 1-(ethylaminocarbonyl)piperidin-4-yl, 1-(*iso*-propylaminocarbonyl)piperidin-4-yl, 1-(ethoxycarbonyl)piperidin-4-yl, 1-(tert-butoxycarbonyl)piperidin-4-yl and 1-(aminocarbonyl)piperidin-4-yl.
4. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R_{na} and R_{nb} are both hydrogen.
5. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein n is 1.
6. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R³ and R⁴ are both hydrogen.
7. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R² is unsubstituted or substituted phenyl.
8. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R² is phenyl substituted with chloro.
9. (Currently amended) A compound of formula (I) according to ~~any one of the preceding claims~~ claim 1 wherein R² is 3,4-dichlorophenyl.
10. – 12. (Cancelled)
13. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);




wherein;

R^1 , Y , R^3 , R^4 , and R^2 are as hereinbefore defined for formula (I) in claim 1 and U is a urea-forming group;

and thereafter, if required, carrying out one or more of the following optional steps:


- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

14. (Original) A compound of formula (III)




wherein U is a urea-forming group and R^2 and R^4 are as defined for formula (I) in claim 1.

15. (Original) A compound of formula (IVBR)



wherein A is a protected amino group and R^2 is as defined for formula (I) in claim 1.

16. (Original) A compound of formula (IVBE)



wherein A is a protected amino group and R² is as defined for formula (I) in claim 1.

17. (Original) A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.

18. (Currently amended) A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. ~~asthma or rhinitis~~.

19. (Currently amended) A method for the manufacture of a medicament for the treatment of inflammatory conditions comprising incorporating Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a in said medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.

20. (Currently amended) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition ~~e.g. asthma or rhinitis~~, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

21. (Original) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.